Relación de la Lipoproteínas de Alta Densidad Disfuncionales y el riesgo cardiovascular en personas con VIH
DOI:
https://doi.org/10.61368/r.s.d.h.v4i2.57Palabras clave:
Lipoproteínas de alta densidad, virus de inmunodeficiencia humana, enfermedades cardiovascularesResumen
El Virus de inmunodeficiencia humana (VIH) ha sido objeto de estudios por más de tres décadas. Actualmente, se ha reconocido la participación del estrés oxidativo y la activación de procesos inflamatorios que hacen susceptibles al hospedero de desarrollar patologías subyacentes que requieren entenderse en el contexto de la enfermedad. Entre las manifestaciones causadas por el desbalance en el metabolismo de lípidos, se encuentra la lipodistrofia, dislipidemia, resistencia a la insulina e hipertensión, factores que incrementan el riesgo cardiovascular. Las investigaciones recientes sugieren que las lipoproteínas de alta densidad (HDL) desempeñan un papel crucial en el incremento del riesgo cardiovascular, no solamente por los cambios en su concentración circulante, sino también por cambios en su función, lo cual ha sido objeto de estudio para crear nuevos tratamientos. Por tanto se realizó una revisión, mediante la búsqueda de información primaria y secundaria en tres bases electrónicas de artículos científicos publicados en el año 1986 a 2023, con el fin de analizar el papel de las HDL en la regulación de procesos oxidativos e inflamatorios en pacientes VIH+, los mecanismos que favorecen su disfuncionalidad, así como las estrategias terapéuticas para disminuir el riesgo cardiovascular al incrementar la funcionalidad de las HDL.
Descargas
Referencias
Almeida LB, Segurado AC, Duran AC, Jaime PC. 2011. Impact of a nutritional counseling program on prevention of HAART-related metabolic and morphologic abnormalities. AIDS care. 23(6), 755–763. https://doi.org/10.1080/09540121.2010.52578
Aparecida E, Falco MO, Santos ASEAC, Noll M, de Oliveira C. 2020. Nutritional Intervention Reduces Dyslipidemia, Fasting Glucose and Blood Pressure in People Living with HIV/AIDS in Antiretroviral Therapy: A Randomized Clinical Trial Comparing Two Nutritional Interventions. Nutrients. 12(10), 2970–. doi:10.3390/nu12102970
Baum MK, Sales S, Jayaweera DT, Lai S, Bradwin G, Rafie C, Page JB, Campa A. 2011. Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami. HIV Med. 12(2):78-86. doi: 10.1111/j.1468-1293.2010.00849.x.
Bavaro, D.F.; Laghetti, P.; Poliseno, M.; De Gennaro, N.; Di Gennaro, F.; Saracino, A. 2021. A Step Closer to the “Fourth 90”: A Practical Narrative Review of Diagnosis and Management of Nutritional Issues of People Living with HIV. Diagnostics 11: 2047. https://doi.org/ 10.3390/diagnostics1111204.
Beatty G, Chu J, Kulkarni K, Lipshutz G, Khalili M, Abbasi F, Stansell J, Reaven GM . 2004. Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients. HIV Clin Trials. 5(6):383-91. doi: 10.1310/NFQX-3GWX-EP7W-68AC.
Bhattacharyya S, Sinha K, Sil PC. 2014. Cytochrome P450s: mechanisms and biological implications in drug metabolism and its interaction with oxidative stress. Curr Drug Metab. 15(7):719-42. doi: 10.2174/1389200215666141125121659.
Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. 2012. Oxidative stress and antioxidant defense. World Allergy Organ J. 5(1):9-19. doi: 10.1097/WOX.0b013e3182439613.
Buckley S, Byrnes S, Cochrane C, Roche M, Estes JD, Selemidis S, Angelovich TA, Churchill MJ. 2021. The role of oxidative stress in HIV-associated neurocognitive disorders. Brain Behav Immun Health. 13:100235. doi: 10.1016/j.bbih.2021.100235.
Calabresi L, Gomaraschi M, Simonelli S, Bernini F, Franceschini G. 2015. HDL and atherosclerosis: Insights from inherited HDL disorders. Biochim Biophys Acta. 1851(1):13-8. doi: 10.1016/j.bbalip.2014.07.015.
Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 256(20):2835-8.
Chen Z, Zhong C. 2014. Oxidative stress in Alzheimer's disease. Neurosci Bull. 30(2):271-81. doi: 10.1007/s12264-013-1423-y.
Chiesa ST, Charakida M. 2019. High-Density Lipoprotein Function and Dysfunction in Health and Disease. Cardiovasc Drugs Ther. 33(2):207-219. doi: 10.1007/s10557-018-06846-w.
Chotivichien S, Arab L, Prasithsirikul W, Manosuthi W, Sinawat S, Detels R. 2016. Effect of nutritional counseling on low-density lipoprotein cholesterol among Thai HIV-infected adults receiving antiretroviral therapy. AIDS care. 28(2), 257–265. https://doi.org/10.1080/09540121.2015.1072127
Cota A, Flores AC, Ling XF, Varella M, Flores SC. 2011. HIV-1 Tat increases oxidant burden in the lungs of transgenic mice. Free Radic Biol Med. 51(9):1697-707. doi: 10.1016/j.freeradbiomed.2011.07.023.
Delgado R. 2011. Características virológicas del VIH [Virological characteristics of HIV]. Enferm Infecc Microbiol Clin. 29(1):58-65. doi: 10.1016/j.eimc.2010.10.001.
Deshpande A, Toshniwal H, Joshi S, Jani RH. 2016. A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy. PloS one. 11(1), e0146222. https://doi.org/10.1371/journal.pone.0146222
Dobmeyer TS, Findhammer S, Dobmeyer JM, Klein SA, Raffel B, Hoelzer D, Helm EB, Kabelitz D, Rossol R. Ex vivo induction of apoptosis in lymphocytes is mediated by oxidative stress: role for lymphocyte loss in HIV infection. Free Radic Biol Med. 22(5):775-85. doi: 10.1016/s0891-5849(96)00403-0.
Dorantes A, Estrada D, Bautista R, Betanzos G, Luna M, Flores C, Vargas G, Fragoso JM, Pérez Ó, Carreón E. 2020. Microencapsulated Pomegranate Modifies the Composition and Function of High-Density Lipoproteins (HDL) in New Zealand Rabbits. Molecules. 25(14):3297. doi: 10.3390/molecules25143297. PMID: 32708063; PMCID: PMC7397439.
Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL. 2018. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents. 52(5):541-553. doi: 10.1016/j.ijantimicag.2018.07.010.
Durstenfeld MS, Hsue PY. 2021. Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV. Curr Opin HIV AIDS. 16(3):177-185. doi: 10.1097/COH.0000000000000681.
Dysangco A, Liu Z, Stein JH, Dubé MP, Gupta SK. 2017. HIV infection, antiretroviral therapy, and measures of endothelial function, inflammation, metabolism, and oxidative stress. PLoS One. 12(8):e0183511. doi: 10.1371/journal.pone.0183511.
Errico TL, Chen X, Martin JM, Julve J, Escola JC, Blanco F. 2013. [Basic mechanisms: structure, function and metabolism of plasma lipoproteins]. Clin Investig Arterioscler. 25(2):98-103. Spanish. doi: 10.1016/j.arteri.2013.05.003.
Estrada D, Carreón E, Bautista R, Betanzos G, Dorantes A, Luna M, Vargas J, Mejía AM, Fragoso JM, Carvajal K, et al. 2019. Microencapsulated Pomegranate Reverts High-Density Lipoprotein (HDL)-Induced Endothelial Dysfunction and Reduces Postprandial Triglyceridemia in Women with Acute Coronary Syndrome. Nutrients. 11(8):1710. doi: 10.3390/nu11081710.
Fanales E, Raimondo M, Suligoi B, Butto S. 2010. HIV virology and pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanita. 46(1):5-14. doi: 10.4415/ANN_10_01_02.
Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. 2010. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol. 4(4), 279–287. https://doi.org/
Figueira TR, Barros MH, Camargo AA, Castilho RF, Ferreira JC, Kowaltowski AJ, Sluse FE, Souza-Pinto NC, Vercesi AE. 2013. Mitochondria as a source of reactive oxygen and nitrogen species: from molecular mechanisms to human health. Antioxid Redox Signal.18(16):2029-74. doi: 10.1089/ars.2012.4729.
Funderburg NT, Xu D, Playford MP, Joshi AA, Andrade A, Kuritzkes DR, Lederman MM, Mehta NN. 2017. Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antivir Ther.22(1):71-75. doi: 10.3851/IMP3091.
Furtado JD, Ruotolo G, Nicholls SJ, Dullea R, Carvajal S, Sacks FM. 2022. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 42(2), 227–237. https://doi.org/10.1161/ATVBAHA.121.317181
Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, et al. 2014. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 63(25 Pt B):2935-2959. doi: 10.1016/j.jacc.2013.11.005.
Hall VP. 2018. Common Gastrointestinal Complications Associated with Human Immunodeficiency Virus/AIDS: An Overview. Crit Care Nurs Clin North Am. 30(1):101-107. doi: 10.1016/j.cnc.2017.10.009.
Henning RJ, Greene JN. 2023. The epidemiology, mechanisms, diagnosis and treatment of cardiovascular disease in adult patients with HIV. Am J Cardiovasc Dis. 13(2):101-121.
Hsue PY, Waters DD. 2019. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol. 16(12):745-759. doi: 10.1038/s41569-019-0219-9.
Huang X, Liang H, Fan X, Zhu L, Shen T. 2016. Liver Damage in Patients with HCV/HIV Coinfection Is Linked to HIV-Related Oxidative Stress. Oxid Med Cell Longev. 2016:8142431. doi: 10.1155/2016/8142431.
Ivanov A.V, Valuev VT, Ivanova ON, Kochetkov SN, Starodubova ES, Bartosch B, Isaguliants MG. 2016. Oxidative Stress during HIV Infection: Mechanisms and Consequences. Oxid Med Cell Longev: 8910396. doi: 10.1155/2016/8910396.
Jiang Y, Chai L, Fasae MB, Bai Y. 2018. The role of HIV Tat protein in HIV-related cardiovascular diseases. J Transl Med. 16(1):121. doi: 10.1186/s12967-018-1500-0.
Jiménez AS, Jaen S, Fernández E, Ortíz MA, Martínez MF, Jiménez RC, Flores OR, Ramírez E, Arias J, Arteaga F,et al. 2022. Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals. Int J Mol Sci. 23(10):5592. doi: 10.3390/ijms23105592.
Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, et al. 2012. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 367(14):1310-20. doi: 10.1056/NEJMoa1107477.
Kelesidis T, Oda MN, Borja MS, Yee Y, Ng KF, Huynh D, Elashoff D, Currier JS. 2017. Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals. J Acquir Immune Defic Syndr. 75(3):354-363. doi: 10.1097/QAI.0000000000001383.
Kobayashi N, Nakahara M, Oka M, Saeki K. 2017. Additional attention to combination antiretroviral therapy-related lipodystrophy. World J Virol. 6(3):49-52. doi: 10.5501/wjv.v6.i3.49.
Kumar D, Bohra GK, Agarwal M, Khichar S, Choudhary S, Midha N. 2018. Prediction of Cardiovascular Disease Risk Using Framingham and Data on Adverse Effect of Antiretroviral Drugs Risk Equation in Relation to Lipodystrophy in HIV Patients on Highly Active Antiretroviral Therapy. J Glob Infect Dis. 10(4):182-187. doi: 10.4103/jgid.jgid_89_17.
Kumar D, Bohra GK, Agarwal M, Khichar S, Choudhary S, Midha N. 2018. Prediction of Cardiovascular Disease Risk Using Framingham and Data on Adverse Effect of Antiretroviral Drugs Risk Equation in Relation to Lipodystrophy in HIV Patients on Highly Active Antiretroviral Therapy. J Glob Infect Dis. 10(4):182-187. doi: 10.4103/jgid.jgid_89_17.
Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 420(6916):678-82. doi: 10.1038/nature01188.
Libby P, Tabas I, Fredman G, Fisher EA. 2014. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 114(12):1867-79. doi: 10.1161/CIRCRESAHA.114.302699.
Limongi D, Baldelli S. 2016. Redox Imbalance and Viral Infections in Neurodegenerative Diseases. Oxid Med Cell Longev. 2016:6547248. doi: 10.1155/2016/6547248.
Lin S, Nadeau PE, Mergia A. 2015. HIV inhibits endothelial reverse cholesterol transport through impacting subcellular Caveolin-1 trafficking. Retrovirology. 12:62. doi: 10.1186/s12977-015-0188-y.
Madsen CM, Varbo A, Tybjærg A, Frikke R, Nordestgaard BG. 2018. U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies. Eur Heart J. 39(14):1181-1190. doi: 10.1093/eurheartj/ehx665.
Mandas A, Iorio EL, Congiu MG, Balestrieri C, Mereu A, Cau D, Dessì S, Curreli N. 2009. Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy. J Biomed Biotechnol. 2009:749575. doi: 10.1155/2009/749575.
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, et al. 2014. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol. 43(3):691-702. doi: 10.1093/ije/dyt010.
Mergia A. 2017.The Role of Caveolin 1 in HIV Infection and Pathogenesis. Viruses. 9(6):129. doi: 10.3390/v9060129.
Musisi E, Matovu DK, Bukenya A, Kaswabuli S, Zawedde J, Andama A, Byanyima P, Sanyu I, Sessolo A, Seremba E, et al. 2018. Effect of anti-retroviral therapy on oxidative stress in hospitalized HIV-infected adults with and without TB. Afr Health Sci. 18(3):512-522. doi: 10.4314/ahs.v18i3.7.
Ng, GW, Chan UM, Li PC, Wong WC. 2011. Can a Mediterranean diet reduce the effects of lipodystrophy syndrome in people living with HIV? A pilot randomised controlled trial. Sexual health. 8(1), 43–51. https://doi.org/10.1071/SH09065
Ngo ME, Pieme CA, Azabji M, Biapa PC, Germaine N, Heike E, Moukette BM, Emmanuel K, Philippe S, Mbofung CM, Ngogang JY. 2014. Effects of Spirulina platensis supplementation on lipid profile in HIV-infected antiretroviral naïve patients in Yaounde-Cameroon: a randomized trial study. Lipids Health Dis. 13: 191. https://doi.org/10.1186/1476-511X-13-191
Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, Madhivanan P, Maziak W. 2017. HIV/HCV coinfection and the risk of cardiovascular disease: A meta-analysis. J Viral Hepat. 24(11):998-1004. doi: 10.1111/jvh.12725.
Otrante A, Trigui A, Walha R, Berrougui H, Fulop T, Khalil A. 2021. Extra Virgin Olive Oil Prevents the Age-Related Shifts of the Distribution of HDL Subclasses and Improves Their Functionality. Nutrients. 13(7), 2235. https://doi.org/10.3390/nu13072235
Payne BA, Gardner K, Chinnery PF.2015. Mitochondrial DNA mutations in ageing and disease: implications for HIV?. Antivir Ther. 20(2):109-20. doi: 10.3851/IMP2824.
Perez O, Pacheco HG, Martinez C, Franco M. 2014. HDL-cholesterol in coronary artery disease risk: function or structure?. Clin Chim Acta. 429:111-22. doi: 10.1016/j.cca.2013.12.001.
Petrilli AA, Souza SJ, Teixeira AM, Pontilho PM, Souza JM, Luzia LA, Rondó PH.2016. Effect of Chocolate and Yerba Mate Phenolic Compounds on Inflammatory and Oxidative Biomarkers in HIV/AIDS Individuals. Nutrients. 8(5), 132. https://doi.org/10.3390/nu8050132
Rader DJ, Hovingh GK.2014. HDL and cardiovascular disease. Lancet. 384(9943):618-625. doi: 10.1016/S0140-6736(14)61217-4.
Ramirez A, Hu PP. 2015. Low High-Density Lipoprotein and Risk of Myocardial Infarction. Clin Med Insights Cardiol. 9:113-7. doi: 10.4137/CMC.S26624.
Reddy PV, Gandhi N, Samikkannu T, Saiyed Z, Agudelo M, Yndart A, Khatavkar P, Nair MP. 2012. HIV-1 gp120 induces antioxidant response element-mediated expression in primary astrocytes: role in HIV associated neurocognitive disorder. Neurochem Int. 61(5):807-14. doi: 10.1016/j.neuint.2011.06.011.
Remaley AT, Norata GD, Catapano AL. 2014. Novel concepts in HDL pharmacology. Cardiovasc Res. 103(3):423-8. doi: 10.1093/cvr/cvu141.
Rizzo M, Otvos J, Nikolic D, Montalto G, Toth PP, Banach M. 2014. Subfractions and subpopulations of HDL: an update. Curr Med Chem. 21(25):2881-91. doi: 10.2174/0929867321666140414103455.
Rodrigo R, Fernández-Gajardo R, Gutiérrez R, Matamala JM, Carrasco R, Miranda-Merchak A, Feuerhake W. 2013. Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities. CNS Neurol Disord Drug Targets. 12(5):698-714. doi: 10.2174/1871527311312050015.
Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, Sviridov D.2006. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism. 55(1):90-5. doi: 10.1016/j.metabol.2005.07.012.
Schaefer EJ, Anthanont P, Diffenderfer MR, Polisecki E, Asztalos BF. 2016. Diagnosis and treatment of high density lipoprotein deficiency. Prog Cardiovasc Dis. 59(2):97-106. doi: 10.1016/j.pcad.2016.08.006.
Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, Longenecker CT, Strachan F, Bagchi S, Whiteley W, et al. 2018. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV. Circulation. 138(11):1100-1112. doi: 10.1161/CIRCULATIONAHA.117.033369.
Sharma B. 2014. Oxidative stress in HIV patients receiving antiretroviral therapy. Curr HIV Res. 12(1):13-21. doi: 10.2174/1570162x12666140402100959.
Teer E, Essop MF. 2018. HIV and Cardiovascular Disease: Role of Immunometabolic Perturbations. Physiology (Bethesda). 33(1):74-82. doi: 10.1152/physiol.00028.2017.
Toribio M, Park MH, Zanni MV, Robbins GK, Burdo TH, Williams KC, Feldpausch MN, Stone L, Melbourne K, Grinspoon SK, et al. 2017. HDL Cholesterol Efflux Capacity in Newly Diagnosed HIV and Effects of Antiretroviral Therapy. J Clin Endocrinol Metab. 102(11):4250-4259. doi: 10.1210/jc.2017-01334.
Turner BG, Summers MF. 1999. Structural biology of HIV. Mol Biol. 285(1):1-32. doi: 10.1006/jmbi.1998.2354.
Van Heuvel Y, Schatz S, Rosengarten JF, Stitz J. 2022. Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. Toxins (Basel). 14(2):138. doi: 10.3390/toxins14020138.
Vos AG, Chersich MF, Klipstein-Grobusch K, Zuithoff P, Moorhouse MA, Lalla-Edward ST, Kambugu A, Kumarasamy N, Grobbee DE, Barth RE, et al. 20118. Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir. Retrovirology. 15(1):77. doi: 10.1186/s12977-018-0460-z.
Vyletelová V, Nováková M, Pašková Ľ. 2022. Alterations of HDL's to piHDL's Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. Pharmaceuticals (Basel). 15(10):1278. doi: 10.3390/ph15101278.
Wang T, Yi R, Green LA, Chelvanambi S, Seimetz M, Clauss M. 2015. Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat. Cardiovasc Pathol. 24(5):279-82. doi: 10.1016/j.carpath.2015.07.001.
Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar JF, Salazar MG, Kilby JM, Saag MS, et al. 2003. Antibody neutralization and escape by HIV-1. Nature. 422(6929):307-12. doi: 10.1038/nature01470.
Williams AA, Sitole LJ, Meyer D.2017. HIV/HAART-associated oxidative stress is detectable by metabonomics. Mol Biosyst. 13(11):2202-2217. doi: 10.1039/c7mb00336f.
Wojcicka G, Jamroz-Wisniewska A, Czechowska G, Korolczuk A, Marciniak S, Beltowski J. 2016. The paraoxonase 1 (PON1), platelet-activating factor acetylohydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin treated normal and diabetic rats. Eur J Pharmacol. 789:187-194. doi: 10.1016/j.ejphar.2016.07.034.
Zhu R, Fogelholm M, Poppitt SD, Silvestre MP, Møller G, Huttunen-Lenz M, Stratton G, Sundvall J, Råman L, Jalo E, et al. 2021. Adherence to a Plant-Based Diet and Consumption of Specific Plant Foods—Associations with 3-Year Weight-Loss Maintenance and Cardiometabolic Risk Factors: A Secondary Analysis of the PREVIEW Intervention Study. Nutrients. 13: 3916. https://doi.org/10.3390/ nu13113916.
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Angélica Saraí Jiménez Osorio , Emmanuel Correa Solís, Elizabeth Carreón Torres, Julieta Ángel García, Olga Rocío Chávez Flores, Diego Estrada Luna
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
